Outcomes:
Colchicine was associated with a significant reduction in AF recurrence
(HR 0.78, 95% CI [0.63, 0.96], P 0.022) (Figure 1). Mean time to AF
recurrence in days were 468±120 days in the colchicine group vs 282±112
days in the no colchicine group.
Patients with persistent AF (HR 1.56, 95% CI [1.27, 1.91],
p<0.001) and those undergoing repeat ablation (HR 1.37, CI
[1.12, 1.67], p=0.002) were more likely to have AF recurrence. More
extensive ablation was performed in the colchicine group (OR 3.69, 95%
CI [2.84, 4.81], p<0.001). Patients with persistent AF (OR
1.95, 95% CI [1.47, 2.59], p<0.001) and older patients
(OR 1.02, 95% CI [1.01, 1.04], p<0.001) required more
extensive ablation.